131 related articles for article (PubMed ID: 35451606)
21. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
22. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
[TBL] [Abstract][Full Text] [Related]
23. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
24. Interobserver Agreement and Positivity of PI-RADS Version 2 Among Radiologists with Different Levels of Experience.
Mussi TC; Yamauchi FI; Tridente CF; Tachibana A; Tonso VM; Recchimuzzi DR; de Souza Leão LR; Luz DC; Martins T; Baroni RH
Acad Radiol; 2019 Aug; 26(8):1017-1022. PubMed ID: 30268722
[TBL] [Abstract][Full Text] [Related]
25. Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies.
Kortenbach KC; Løgager V; Thomsen HS; Boesen L
Abdom Radiol (NY); 2023 Feb; 48(2):688-693. PubMed ID: 36318331
[TBL] [Abstract][Full Text] [Related]
26. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
[TBL] [Abstract][Full Text] [Related]
27. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
28. Impact of PI-QUAL on PI-RADS and cancer yield in an MRI-TRUS fusion biopsy population.
Pötsch N; Rainer E; Clauser P; Vatteroni G; Hübner N; Korn S; Shariat SF; Helbich TH; Baltzer PAT
Eur J Radiol; 2022 Sep; 154():110431. PubMed ID: 35803101
[TBL] [Abstract][Full Text] [Related]
29. Central zone lesions on magnetic resonance imaging: Should we be concerned?
Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
[TBL] [Abstract][Full Text] [Related]
30. Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI.
Rosenkrantz AB; Lim RP; Haghighi M; Somberg MB; Babb JS; Taneja SS
AJR Am J Roentgenol; 2013 Oct; 201(4):W612-8. PubMed ID: 24059400
[TBL] [Abstract][Full Text] [Related]
31. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
32. Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
Viana PCC; Horvat N; do Santos VR; Lima TC; Romão DDS; Cerri LMO; de Castro MG; Vargas HA; Miranda JA; Leite CDC; Cerri GG
Int Braz J Urol; 2019; 45(4):724-731. PubMed ID: 31136114
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.
Wang X; Bao J; Ping X; Hu C; Hou J; Dong F; Guo L
Oncol Lett; 2018 Sep; 16(3):3201-3206. PubMed ID: 30127915
[TBL] [Abstract][Full Text] [Related]
34. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric magnetic resonance imaging - Transrectal ultrasound-guided cognitive fusion biopsy of the prostate: Clinically significant cancer detection rates stratified by the Prostate Imaging and Data Reporting System version 2 assessment category.
John S; Cooper S; Breau RH; Flood TA; Cagiannos I; Lavallee LT; Morash C; O'sullivan J; Schieda N
Can Urol Assoc J; 2018 Dec; 12(12):401-406. PubMed ID: 29940139
[TBL] [Abstract][Full Text] [Related]
36. Inter-Reader Variability Using PI-RADS v2 Versus PI-RADS v2.1: Most New Disagreement Stems from Scores 1 and 2.
Beetz NL; Haas M; Baur A; Konietschke F; Roy A; Hamm CA; Rudolph MM; Shnayien S; Hamm B; Cash H; Asbach P; Penzkofer T
Rofo; 2022 Aug; 194(8):852-861. PubMed ID: 35545106
[TBL] [Abstract][Full Text] [Related]
37. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
[TBL] [Abstract][Full Text] [Related]
38. Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
Hamm CA; Baumgärtner GL; Padhani AR; Froböse KP; Dräger F; Beetz NL; Savic LJ; Posch H; Lenk J; Schallenberg S; Maxeiner A; Cash H; Günzel K; Hamm B; Asbach P; Penzkofer T
Eur Radiol; 2024 Mar; ():. PubMed ID: 38538841
[TBL] [Abstract][Full Text] [Related]
39. Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy.
Wang YH; Liang C; Zhu FP; Zhou TR; Li J; Wang ZJ; Liu BJ
Asian J Androl; 2023; 25(2):217-222. PubMed ID: 36722578
[TBL] [Abstract][Full Text] [Related]
40. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies.
Ukimura O; Marien A; Palmer S; Villers A; Aron M; de Castro Abreu AL; Leslie S; Shoji S; Matsugasumi T; Gross M; Dasgupta P; Gill IS
World J Urol; 2015 Nov; 33(11):1669-76. PubMed ID: 25656687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
